[
    [
        {
            "time": "",
            "original_text": "CRO&CDMO投研体系之数据跟踪(系列四)：2020H1回顾与前瞻 疫情背景下中国企业竞争优势凸显",
            "features": {
                "keywords": [
                    "CRO",
                    "CDMO",
                    "投研体系",
                    "数据跟踪",
                    "2020H1",
                    "疫情",
                    "竞争优势",
                    "中国企业"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "CRO&CDMO投研体系之数据跟踪(系列四)：2020H1回顾与前瞻 疫情背景下中国企业竞争优势凸显",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：估值步入合理区间 关注超跌个股",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业日报",
                    "估值",
                    "合理区间",
                    "超跌个股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业日报：估值步入合理区间 关注超跌个股",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]